18/09/2026 US FDA approves Inluriyo + Verzenio for ESR1-Mutated ER+/HER2− Metastatic Breast Cancer Japan Approves Keytruda SC, Expanding Global Commercialization of Alteogen's ALT-B4 Platform Amneal Announces US FDA Approval and Launch of Lanreotide Injection US FDA approves Inluriyo + Verzenio for ESR1-Mutated ER+/HER2− Metastatic Breast Cancer (Ref) Eli Lilly announced that the U.S. FDA has granted full approval to Inluriyo (imlunestrant; estrogen receptor antagonist) + Ver

04/06/2026 Amneal secures FDA nod and 180‑day CGT exclusivity for ready‑to‑use romidepsin injection in cutaneous T‑cell lymphoma Amneal secures FDA nod and 180‑day CGT exclusivity for ready‑to‑use romidepsin injection in cutaneous T‑cell lymphoma (Ref) Amneal received US FDA approval for its romidepsin injection solution (27.5 mg/5.5 mL), supplied in ready-to-use vials Competitive Generic Therapy (CGT): The product qualifies for CGT designation, granting 180 days of market ex